Porter, Charlene <br/><br/>
Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer.  [electronic resource] 

 -  Journal of reproductive immunology  08 2016 
 - 7-12 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1872-7603 
<br/><br/><label>Standard No.: </label>10.1016/j.jri.2016.04.284  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab--metabolism<br/>Cells, Cultured<br/>Certolizumab Pegol--metabolism<br/>Female<br/>Histocompatibility Antigens Class I--metabolism<br/>Humans<br/>Immunoglobulin G--metabolism<br/>Infliximab--metabolism<br/>Organ Culture Techniques<br/>Placenta--metabolism<br/>Placental Circulation<br/>Pregnancy<br/>Protein Binding<br/>Receptors, Fc--metabolism<br/>Transcytosis<br/>Tumor Necrosis Factor-alpha--immunology